Abstract
Taxanes (paclitaxel and docetaxel) are among the most active cytotoxic agents in use in oncology, being widely used in adjuvant and advanced treatment settings in multiple tumor types. Due to the impressive benefits offered by the taxanes, different strategies are in development, aimed at reducing their systemic toxicity and the need for premedication, while improving anti-tumor spectra and treatment efficacy. Although a remarkable amount of effort has been aimed at overcoming delivery difficulties, very few compounds have reached clinical trials, and some of those few have failed advanced trials. This mini-review reports the most recent developments in advanced taxane delivery approaches, with particular focus on receptor-targeted delivery systems.
Keywords: Taxanes, conjugates, micelles, nanoparticles, chemotherapy, cancer, drug delivery, cancer cells, EGFR, POLYMERIC MICELLES
Drug Delivery Letters
Title: Targeted Taxane Delivery Systems: Recent Advances
Volume: 1 Issue: 2
Author(s): Daniela Gastaldi, Daniele Zonari and Franco Dosio
Affiliation:
Keywords: Taxanes, conjugates, micelles, nanoparticles, chemotherapy, cancer, drug delivery, cancer cells, EGFR, POLYMERIC MICELLES
Abstract: Taxanes (paclitaxel and docetaxel) are among the most active cytotoxic agents in use in oncology, being widely used in adjuvant and advanced treatment settings in multiple tumor types. Due to the impressive benefits offered by the taxanes, different strategies are in development, aimed at reducing their systemic toxicity and the need for premedication, while improving anti-tumor spectra and treatment efficacy. Although a remarkable amount of effort has been aimed at overcoming delivery difficulties, very few compounds have reached clinical trials, and some of those few have failed advanced trials. This mini-review reports the most recent developments in advanced taxane delivery approaches, with particular focus on receptor-targeted delivery systems.
Export Options
About this article
Cite this article as:
Gastaldi Daniela, Zonari Daniele and Dosio Franco, Targeted Taxane Delivery Systems: Recent Advances, Drug Delivery Letters 2011; 1 (2) . https://dx.doi.org/10.2174/2210304x11101020105
DOI https://dx.doi.org/10.2174/2210304x11101020105 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aerosol Processing of Crumpled Graphene Oxide-based Nanocomposites for Drug Delivery
Current Pharmaceutical Design Application of NMR to the Study of Cells and Body Fluids
Current Organic Chemistry Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells
Current Drug Delivery Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design De Novo DNMTs and DNA Methylation: Novel Insights into Disease Pathogenesis and Therapy from Epigenomics
Current Pharmaceutical Design Telomeric G-Quadruplex Architecture and Interactions with Potential Drugs
Current Pharmaceutical Design DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design CD36-TSP-HRGP Interactions in the Regulation of Angiogenesis
Current Pharmaceutical Design Molecular Markers of Glial Tumors: Current Targeting Strategies
Current Medicinal Chemistry Circumventing Melanoma Chemoresistance by Targeting DNA Repair
Current Medicinal Chemistry Germacrone: A Potent Secondary Metabolite with Therapeutic Potential in Metabolic Diseases, Cancer and Viral Infections
Current Drug Metabolism Lipid Based Anti-Retroviral Nanocarriers: A Review of Current Literature and Ongoing Studies
Drug Delivery Letters MicroRNA-136 Promotes Vascular Muscle Cell Proliferation Through the ERK1/2 Pathway by Targeting PPP2R2A in Atherosclerosis
Current Vascular Pharmacology Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design Nanomedicine: Magnetic Nanoparticles and their Biomedical Applications
Current Medicinal Chemistry A Potent Anti-Carcinoma and Anti-Acute Myeloblastic Leukemia Agent, AG490
Anti-Cancer Agents in Medicinal Chemistry The Disposal of Reactive Carbonyl Species through Carnosine Conjugation: What We Know Now
Current Medicinal Chemistry Pharmacological Approaches to Targeting Muscarinic Acetylcholine Receptors
Recent Patents on CNS Drug Discovery (Discontinued) Effect of Salinomycin on Expression Pattern of Genes Associated with Apoptosis in Endometrial Cancer Cell Line
Current Pharmaceutical Biotechnology Inflammation and Antiangiogenesis in Cancer
Current Medicinal Chemistry